De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1943-4596
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer ; volume:13 ; number:3 ; day:14 ; month:6 ; year:2021 ; pages:151-156 ; date:9.2021
Current breast cancer reports ; 13, Heft 3 (14.6.2021), 151-156, 9.2021
- Urheber
-
Gonzalez, Lorena
Mortimer, Joanne
Kruper, Laura
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12609-021-00421-3
- URN
-
urn:nbn:de:101:1-2021110609145093903156
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gonzalez, Lorena
- Mortimer, Joanne
- Kruper, Laura
- SpringerLink (Online service)
Ähnliche Objekte (12)
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
Metastatic Triple-Negative Breast Cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
Metastatic Triple-Negative Breast Cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
Metastatic Triple-Negative Breast Cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance